黑色素瘤耐药机制研究:ABL1/2驱动免疫逃逸,Nilotinib干预展现潜力
Study reveals how melanoma outmaneuvers both drugs and immune defenses
Nature Communications发表研究证实,黑色素瘤中ABL1和ABL2蛋白激活ERK信号并招募免疫抑制细胞,导致MAPK抑制剂耐药及免疫防御失效。在临床前模型中,已获批用于慢性粒细胞白血病的Nilotinib通过阻断ABL蛋白,成功关闭肿瘤生长信号并恢复T细胞功能。该结果确立了ABL激酶作为治疗靶点的价值,为结合免疫系统的联合治疗策略提供了依据。
Melanoma is one of the most difficult cancers to treat due to its resistance to targeted drug therapies. But a new study from the University of Kentucky Markey Cancer Center shows that the cancer is playing offense as well as defense: In addition to forming resistance against the MAPK inhibitors that are commonly used to treat it, the cancer also actively suppresses the immune cells that would otherwise help eliminate it.
The study, published in Nature Communications, identified two cell proteins known as ABL1 and ABL2 as key drivers of both processes. These proteins help control cell functions such as growth, survival and communication with other cells, leading to tumor growth when they become overactive. In melanomas, they help the cells keep growing despite treatment by reactivating the growth signals. Meanwhile, they can also trigger a signal that recruits immune-suppressing cells while keeping cancer-fighting T cells at bay.
"These findings reveal that treatment resistance isn't happening only inside the melanoma cell," said UK College of Medicine researcher Rakshamani Tripathi, Ph.D. "ABL1 and ABL2 also help reshape the tumor's immune environment, essentially creating another layer of protection that allows the cancer to survive therapy."
But scientists are working on a new play: Nilotinib is a drug that is Food and Drug Administration–approved for chronic myeloid leukemia, and it works by blocking ABL proteins. Markey researchers have used nilotinib against multiple melanoma cell lines in preclinical testing models, with encouraging results: It shut down the proteins' growth and survival signals and reduced the cancer's ability to attract immune-suppressing cells, which allowed T cells to return.
These findings confirm melanoma's ABL proteins as a therapeutic target, opening up new possibilities for effective treatment.
"What makes this approach promising is the possibility of attacking resistance from two directions by blocking the cancer's survival signals while allowing the immune system to reengage," said Rina Plattner, Ph.D., professor in the UK College of Medicine Department of Pharmacology and Nutritional Sciences. "Our results provide a strong rationale for continuing to study this strategy and translating it into clinical care."
Publication details
Rakshamani Tripathi et al., Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition, Nature Communications (2026). DOI: 10.1038/s41467-026-76864-y
Journal information: Nature Communications
Key medical concepts
Clinical categories
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Study reveals how melanoma outmaneuvers both drugs and immune defenses (2026, October 22) retrieved 22 October 2026 from https://medicalxpress.com/news/2026-10-reveals-melanoma-outmaneuvers-drugs-immune.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com